Barros-Silva Daniela, Marques C Joana, Henrique Rui, Jerónimo Carmen
Cancer Biology and Epigenetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Rua António Bernardino Almeida, 4200-072 Porto, Portugal.
Genetics, Department of Pathology, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal.
Genes (Basel). 2018 Aug 23;9(9):429. doi: 10.3390/genes9090429.
DNA methylation is an epigenetic modification that plays a pivotal role in regulating gene expression and, consequently, influences a wide variety of biological processes and diseases. The advances in next-generation sequencing technologies allow for genome-wide profiling of methyl marks both at a single-nucleotide and at a single-cell resolution. These profiling approaches vary in many aspects, such as DNA input, resolution, coverage, and bioinformatics analysis. Thus, the selection of the most feasible method according with the project's purpose requires in-depth knowledge of those techniques. Currently, high-throughput sequencing techniques are intensively used in epigenomics profiling, which ultimately aims to find novel biomarkers for detection, diagnosis prognosis, and prediction of response to therapy, as well as to discover new targets for personalized treatments. Here, we present, in brief, a portrayal of next-generation sequencing methodologies' evolution for profiling DNA methylation, highlighting its potential for translational medicine and presenting significant findings in several diseases.
DNA甲基化是一种表观遗传修饰,在调节基因表达中起关键作用,因此影响多种生物学过程和疾病。新一代测序技术的进步使得能够在单核苷酸和单细胞分辨率下对甲基化标记进行全基因组分析。这些分析方法在许多方面存在差异,如DNA输入量、分辨率、覆盖范围和生物信息学分析。因此,根据项目目的选择最可行的方法需要对这些技术有深入的了解。目前,高通量测序技术在表观基因组分析中被广泛应用,其最终目的是寻找用于检测、诊断、预后和预测治疗反应的新型生物标志物,以及发现个性化治疗的新靶点。在此,我们简要介绍用于DNA甲基化分析的新一代测序方法的演变,强调其在转化医学中的潜力,并展示在几种疾病中的重要发现。